Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 6281 - 6288 of 12007 results

ML Strategies Health Care Preview - Week of February 12th
February 12, 2018| Blog| Viewpoint

The Administration's Budget Proposal for FY2019
February 12, 2018| Blog| Viewpoint

Immigration Debate Begins: Prospects for EB-5 Reform & Reauthorization
February 12, 2018| Blog| Viewpoint

The First Circuit Casts a Shadow on Sunbeam
February 12, 2018| Blog| Viewpoint

DOJ Reaches Settlement with Michigan Hospital on Allegedly Unlawful Marketing Agreement
February 12, 2018| Alert| Viewpoint

Massachusetts Highest Court Holds Sick Pay is Not a Wage Under the Massachusetts Wage Act
February 9, 2018| Blog| Viewpoint

Mintz’s Health Care Enforcement Defense Group Releases New Qui Tam Update
February 8, 2018| Blog| Viewpoint

The New Extender Timeline
February 8, 2018| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
